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A B S T R A C T
Drug-eluting implants with a polymeric matrix are currently widely used and the interest of modeling their
behavior is increasing. This article aims to present preliminary results of an in vitro under steady flow, study the
behavior of drug-loaded polyurethane samples used as drug delivery matrices. Polyisocyanate and polyol
synthesis supplied the polyurethane studied in this work. A molding and heat at 50 °C for about 30 min make it
possible to prepare films from these components. The prepared samples are placed in the impermeable Plexiglas
tube and they are in contact with the medium (distilled water). Tests have been performed without flow and
three other cases with steady flow, at a temperature of 37 °C. The substance active incorporated in these films, as
the drug, for carrying out the release tests is the C20H24C12N2O3. This drug supplied in granular form is com-
posed of a mixture in the following proportions, 15 mg of diclofenac epolamine and 50 mg of diclofenac-sodium.
Four sample variants were carefully prepared: pure-PU and PU loaded in a mass ratio of 10, 20 or 30%.
Weighing, DSC, FT-IR, and DMTA are the methods used to analyze the samples. In addition, SEM micrographs
are used to explore qualitatively the microstructure during the release tests. The kinetics in vitro of the drug
release and water absorption by the polyurethane films are discussed in detail. The results show that these two
quantities depend on the initial drug loading and the flow rate value, as a function of the in vitro incubation
time.
1. Introduction
Drug release and associated kinematics represent a key issue in
various applications in the industrial fields of nutrition, biology,
therapy, cosmetics, pharmacy, and coatings. The targeted drug ad-
ministration and control of the corresponding time-release demand
sophisticated technological development [1]. There are different ways
of drug delivery. Orally [2], localized, magnetic or transdermal [3–5].
The controlled release of drugs is conditioned by certain aspects to
increase the effectiveness of the therapy. These include, for example,
the evolution and period of release, and the accuracy of the location of
the drug carrier [6]. Therefore, the challenges encountered in this area
of research are to minimize the risk of overall toxicity, to reduce side
effects and to improve the efficacy of treatment [7]. Depending on the
types of drug delivery, various carriers may be considered. Polymeric
delivery agents are becoming increasingly important because of the
several possibilities they offer. The permeability of the polymer matrix,
glass transition temperature, viscosity, degradation, and polymer
concentration represent the effective parameters that regulate the re-
lease of the drug through the matrix [2]. Hydrophilic polymers are good
candidates here because they are provided with pores facilitating the
release of the drug, particularly in the case of poorly soluble drugs.
Because of its biocompatibility, biodegradability, good mechanical
properties, strength, elasticity, non-toxicity and reasonable price,
polyurethane is the most widely used polymer [8,9]. In biological ap-
plications, the polyurethane is employed in the form of films, foams,
and composites [10,11]. For example in Ref. [12], Shin et al. have used
the polyurethane films as a stent coating for cancer therapy. They
confirmed the importance of the initial drug loading on the release rate
and the lag time. Burst release is more prevalent in the case of a film
with a high initial drug load compared to a low load film. In many
studies [8,13,14,15,and16]], the polymer films are prepared in the
form of a composite mixed with various drugs like anti-inflammatories
(Cefazolin, Naltrexone and Piroxicam), anti-thromboses, im-
munosuppressants, anti-proliferative … In the study [17], King et al.
have studied release of Gentamicin from magnesium foams in the
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orthopedic implants. The results showed the drug release for the im-
plants of 25% of Gentamicin was more prominent than for 10%. The
release kinetics of the drug is also dependent on the aqueous solubility,
the chemical structure and physicochemical properties of the drug
[18,19]. It is considered that drugs with high solubility release faster
than drugs with low solubility. In the study [20], Chen et al. have
studied the Gefitinib release from various drug-loaded PU foams. They
have concluded the drug was released with a diffusion mechanism,
where it was observed that the drug release rate is increased with the
drug content. There are some devices to better control drug release
profiles, like the use of drug delivery carriers [21], micro-sponges for
hydrophobic drugs [22], or the use of barriers layers of a polymer
without drug [16,23]. In the study [13], Vahedi et al. have revealed
that the flow conditions influence the release profile by acting on the
penetration depth of the fluid. Many other studies have also revealed
this effect [24–26]. Depending on the property of degradation, me-
chanisms of release can be distinct. In the case of durable polymers, the
dominant release mechanism is assumed diffusion, where factors like
polymer thickness, percent drug, polymer permeability, drug solubility
in the polymer and properties of fluid are influential factors [27–30]. In
a study by Gao et al. [31], on the release of the Antituberculosis drugs
from nanoparticles tested at various mediums with different pH, it was
mentioned that the release rate in the acidic medium was the higher.
For the biodegradable polymer in addition to the diffusion mechanism,
other mechanisms such as swelling or hydrolysis may be present. It
should be mentioned that the hardness, the friability [32] and the
composition of the carriers, affect the mechanisms of release [33]. In
most cases, the temperature is considered constant to body temperature
(37 °C). However, in Ref. [34] Ye et al. found that the increase in
temperature significantly changed the drug release profile from PLGA
progesterone microspheres, because of mechanism change. In the dif-
fusion-controlled system, the drug is released through the pores, poly-
meric membranes and chains. In the diffusion-controlled system, the
release is dependent on the concentration of the drug in the matrix. In
this case, the drug is homogeneously dispersed in the matrix. Indeed,
the release of the drug away from the release surfaces, the water or the
medium, takes longer to migrate through the thickness of the polymer
[2,35]. This study is applicable in all cases of drug delivery as stents,
ear pads, patches, and contact lenses [6,34,36–41]. In all these cases,
some parameters have importance like the geometry of the drug
holders, glass transition temperature, viscosity, drug percentage, drug
type, coating thickness, and release kinetics [6,28]. For matrix-type
devices drug release is more likely to be diffusion-driven which is as-
sociated with the concentration gradient, diffusion distance and degree
of swelling [42]. In this study, polyurethane is considered as matrix
type devices. Drug particles are dispersed in the matrix (Fig. 1). When
the samples are placed in the aqueous medium, water diffuses into the
polymer. This phenomenon is likely related to the thickness, perme-
ability of PU and drug concentration gradient. In this article, the
polyurethane-based films with some percentages of Flector are utilized
to prolong and to regulate the release of drug at different flow rates.
The organization of this work is as follow: sample preparation, test
equipment and procedure of measuring are presented, the essential
physicochemical characteristics and microstructure of polyurethane
and diclofenac epolamine through different tests are presented. In ad-
dition, the results taking into account the effects of the percentage of
the drug and the flow rate values are presented. At the last section of
the paper, particular attention is devoted to the analysis of the phe-
nomenon.
2. Materials description
2.1. Preparation of the polyurethane (PU)
Polyurethane represents the exclusive type of polymer that can
belong to the families of thermoplastics, elastomers, and thermosets. Its
synthesis is from the reaction between a component of each family of
polyols and diisocyanate. The choice of components and of the synth-
esis process delivers the prepared polyurethane for the desired specific
properties [43]. Because of this assortment, PU is used in many pro-
ducts like adhesives, coatings, vehicle parts, sponges, implants and
biological devices and organs [44]. The polyurethane prepared in the
present work is durable. It is a result of the synthesis of hardener
consists of Isocyanate type 4,4-diphenylmethylene diisocyanate (MDI)
and resin composed of polyol, dye, and catalyst. The ultimate product
consists of a mixture of the resin and the hardener in a ratio of five to
two, giving to the instructions provided in the supplier's manual. All of
these products are purchased from the RAIGI Company. The manu-
facture of a film of this polymer gets by molding and heating in an oven
at 50 °C for about 30 min.
2.2. Diclofenac epolamine, flector
The substance incorporated in PU samples for drug release
Fig. 1. Schematic diagram of drug transport.
Fig. 2. Chemical formula of a) Diclofenac (right side)-epolamine(left side) and b) Polyurethane.
experiments is diclofenac epolamine with the trade name of Flector®.
Diclofenac supply a nonsteroidal anti-inflammatory drug (NSAID).
Epolamine is a pharmacologically inactive salt manipulated here to
saline diclofenac, consequently improving its hydrophilic and lipophilic
potencies. The Flector is, therefore, an interesting substance to ad-
minister [45]. Its chemical formula is C20H24Cl2N2O3. The used Flector
supplied by the Genevrier laboratory. It is supplied in granular form
and is composed of 65 mg of diclofenac epolamine including 50 mg of
diclofenac sodium and its density is about 450.7 mg/ml. The solubility
of Flector in the water at 25 °C is about 2.37 mg/l [17]. In a study by
Ahnfelt [46], they have seen that increasing the stirring rate in the
aqueous solution increases the transport of the diclofenac. Fig. 2 shows
the chemical formula of the diclofenac epolamine and polyurethane.
2.3. Preparation of the PU samples loaded with the flector
For drug release experiments, we opted for the thin polymer film
option of approximately 2 mm. The process of preparing the loaded
polymer films is similar to that mentioned in section 2.1 for making
ready of the unloaded polyurethane. Except, that of the initial pre-
paring of mixtures, which are containing a certain dose of Flector. For
each prepared mixture, the maintenance of the Flector dose in granules
form was monitored. Indeed, it has been unobserved of dissolving of
this substance in the polymer, especially in the polyol. Fig. 3 proves this
observation. Four sample variants were carefully prepared: pure-PU
and PU loaded with of the Flector in a mass-ratio of 10, 20 or 30% of
Fig. 3. Optical microscopic observations of the diclofenac epolamine mixture with the polyol a) before and b) after 30 min in the oven at 50 °C.
Fig. 4. Schematic pictures of the fabrication of PU samples loaded with the
Flector. Mold and blanking tools of the samples.
Fig. 5. Test bench components flow-less
case and steady flow case 1) Pump 2)
Electrical engine of the pump 3) Electronic
controller of the pump 4) Reservoir 5)
Inverter 6) Feeding pipe 7) Ramp 8) Test
tube/specimen 9) Shut-off valve 10)
Arterial segment 11). Connections (of the
specimen to the circuit) 12) Fluid return
manifold 13) By pass 14) Adjustable cross-
section restriction 15) Pressure sensor of the
pump 16) Flow sensor 17) Pressure con-
troller 18) Feeding environment 19) and
20) Means of sampling 21) Temperature
controlled enclosure.
the polymer film. The finals samples fabricated are of the dimensions
30×5×2 mm3, cut employing with the cutting tool shown in Fig. 4.
3. Experimental procedure
3.1. Test bench components
Fig. 5 shows the test bench used in the distinct cases of flow rates,
from flow less to the highest flow rate. Valves are operated to regulate
this flow rate. The capacity of the tank used represents 10 L liters of
liquid. Every 2 days of use, this volume is refreshed to eliminate the risk
of saturation.
3.2. Measuring protocol
The three principle steps of the elaborated protocol for measuring
the amounts of drug release and water absorption describe below. This
is a gravimetric method where each test has been repeated three times
Fig. 6. Algorithm of the protocol of the test.
to make sure its repeatability. In the first step, the unloaded and un-
loaded samples are dried in the oven at 50 °C for 1h to remove any
absorbed moisture. Then they were placed in a desiccator to cool.
Immediately upon cooling the specimens are weighed (m0) by using
balance with the precision of 10 μm. The second step is to place the
samples in vitro. After an established time for each sample, these
samples are collected from the test, for beginning the ultimate step. The
third step consists to wipe the surface of the taken samples with a dry
cloth to remove any water present. These samples then weighed (m1)
and placed in an oven at 50 °C to extract the absorbed water during the
stay in vitro. Drying in the oven maintained until the mass of the sample
is stabilized. At this time, the mass of each sample recorded again (m2).
Fig. 6 schematizes this measuring protocol. The experiments were re-
peated in triplicate and the mean value ± standard deviation is re-
ported in the results.
Calculation formulas of wet mass, water absorption and drug release
are presented as following:
= ×m m
m




Water absorption (%) 1002 1
0 (2)
= ×m m
initial mass of drug
Drug release(%) 1002 0
(3)
Where m0 represents the sample mass in the initial state; m1 the mass
after drying with tissue and m2 the mass after drying in the oven.
Fig. 7. SEM micrographs: a) Flector b) PU+10%wt (300 μm) c) PU+10%wt (1 mm) d) PU+20%wt (1 mm) and e) PU+30%wt (1 mm) from the thickness side of the
samples after 1 h of the test.
Fig. 8. DSC results: a) Polyurethane b) Flector c) components of polymer and mixed with drug d) PU loaded 10% mass of Flector and e) PU loaded 20% mass of
Flector at various times of flow-less state test.
Fig. 9. DMTA curve of: a) PU, b) PU loaded 10% mass of Flector at various times and flow-less state.
Fig. 10. IR results of a) pure polyurethane and b) Flector.
Fig. 11. Comparison of pure polyurethane with polyurethane mixed with 10% of Flector.
3.3. Characterization methods
• Microscopic observations: Scanning Electronic Microscope
“HITACHI 4800 SEM” uses to investigate qualitatively the evolution
of the samples microstructure during the test.
• Differential Scanning Calorimetry test, DSC: DSC Q10 V9.0 appa-
ratus is utilized to find out the heat exchange evolution, of the near
the glassy temperature up to the melting point. A slight piece of
6,2 mg of each sample and the Flector placed in hermetic aluminum
capsules, are first equilibrated at −60 °C or 25 °C, respectively.
Then heated at a rate of 5 °C/min up to 200 °C or to 250 °C. This
process replicated two times successively for each sample to elim-
inate the thermal history effect of the material.
• Dynamic thermomechanical analysis, DMTA: For DMTA tests the
device Dynamic Mechanical Analyzer type Q800 V21.2 was used.
The dimensions of the rectangular specimens are approximately 30
× 5 × 2 mm3. The tests are carried out over the entire temperature
range of the apparatus at −100 to 200 °C with the step of 2.00 °C/
min, at frequency of 0.1 Hz, and at constant amplitude. The storage
and loss modulus are measured fitting to the temperature, and their
corresponding values are calculated in this way.
• Fourier transform infrared spectroscopy (FTIR): For FTIR the mea-
surement method employing a potassium bromide (KBr) powder
transmission technique is the one used to produce the infrared
spectra of the Flector granules and for the polyurethane samples
loaded with drug granules reflection method is the methods which is
used.
• Gravimetric analysis: The samples weighed with the “Mettler
H35AR” balance with an accuracy of 0.1 mg.
4. Experimental procedure
4.1. Characterization methods
4.1.1. Analysis of the microstructure
Fig. 7 shows the micrographs of Flector, pore sizes in the PU+10%
wt and polyurethane loaded samples after 1 h of the test. Fig. 7(a)
shows that the average size of the Flector particles is about 40 μm.
Comparing Fig. 7(a) and (b) indicates that the size of the pores is rather
equal to the Flector particles. Micrographs 7 (b), (c), (d) and (e), in-
dicate for the drug-loaded samples that:
• Mass loss is followed by rapid release of the drug;
• For very low concentrations of drug, some particles can be isolated
in the matrix and so not ever come into contact with the water;
• The pores are unconnected to each other;
• The created voids are more for the more elevated concentrations;
• A risk of percolation exists for the samples of higher drug; the voids
are closer, and the possibility of a connection between these spaces
is included to the fact that it establishes the connection for the cir-
culation of the liquid, which causes the rapid release of the medi-
cine. In conclusion, the size, concentration and distribution of the
drug particles in the matrix represent factors that may affect the
drug release.
• However, the porous matrix is helping release of the drug from the
matrix [47] but its optimized content depends to the aim of the use.
4.1.2. DSC analysis
To investigate the heat exchange evolution of PU polymer and
Flector with the temperature variations, DSC technique is used.
Fig. 8(a) shows PU has any transition around 37 °C. Since it is an
amorphous polymer, it does not provide a crystalline temperature or a
melting point. Therefore, its thermal stability is compatible with body
Fig. 12. IR results of samples with PU+10% of Flector after quasi-static test.
Fig. 13. Height of peak (1224.65) from IR results for the samples of PU+10%,
PU+20% and PU+30% of drug at flow-less state test.
temperature. Fig. 8(b) shows that Flector includes an endothermic
phase transition near to 100 °C. Fig. 8(c) shows respectively three DSC
results; a drop of polyol alone, a drop of the polyol with the drug, and a
drop of polyol, isocyanate, and drug. These results make it possible to
assert there is no chemical reaction between the drug and the polymer
and in particular between the polyol and the drug. Indeed, all the peaks
observed indicate there is phase separation between the drug and the
polymer. The unique reaction observed is that of the synthesis of the
polymer corresponding to the peak present at 50 °C and shown in a
dashed red line. DSC result of Flector shows a peak at 100 °C.
Fig. 8(d) and (e) show the amplitude of the Flector peak for a flow-
less test. This peak decreases with the incubation time and it is pre-
sented for two concentrations, 10% and 20% mass of Flector. The
amplitude of this peak is an indicator for evaluating the concentration
of the drug in the polymer.
4.1.3. Dynamic thermo-mechanical analysis
Fig. 9(a) shows the DMTA results of the PU over a temperature
range of −65 to 25 °C. The storage modulus decreases sharply after
−43 °C and stays practically constant close of −20 °C. The glass
transition temperature identified at about −43 °C the material does not
have any transition near the body temperature. For the PU loaded of
10% mass of Flector, Fig. 9(b) shows that the glass transition tem-
perature does not change during the tests at the flow-less state and at
various times.
In addition, water absorption and drug release have not any effect
on the glass transition temperature. In contrast, one can note the
decrease of the modulus in accordance to the time of the flow-less test
for the samples of 10% of Flector at 37 °C. By comparing Fig. 9(a) and
(b) one can note that by adding 10% of drug to the polymer the mod-
ulus of the polymer is decreasing from 22.7 GPa to 1.89 GPa, which can
affect the maintenance of the drug in the polymer by changing the drug
quantity. As the complex modulus is an indicator of how efficiently a
material loses energy to molecular rearrangements and internal fric-
tion. Therefore, can give an idea to determine how well a material will
stand up.
4.1.4. Infrared spectroscopy (IR)
Fig. 10 shows the infrared spectra of the polyurethane and Flector,
some peaks are presented. The important peaks related to Flector are as
follow: 3392 cm−1 related to the N–H amine stretching bound,
1419 cm−1 relates to C]O carboxyl ion and 644 cm−1 for C–Cl
stretching movement. A question is therefore submitted: would this
property allow differentiating the samples agreeing to their drug-
loading rate? To respond this question, the IR spectrum of a pure-PU
sample is compared in Fig. 11 with that of a charged PU, for example,
10% mass of Flector. As can be seen, there are differences in amplitude
between the emerging peaks of each of the two spectra. By way of
example, mention may be made chiefly of those identified at the fol-
lowing wavelengths: 3315, 1710, 1535, 1225 and 820. Other peaks
between 400 and 1500 are not clearly visible in the spectra since all the
characteristic peaks of drug and PU are also in that region. However,
peak shifts can be visible. In the similar way, one can also compare the
spectra of the same sample analyzed at different in vitro times. Fig. 12
Fig. 14. a) Wet mass b) Water absorption and c) Drug release percentage for PU with different percentage of Flector in flow-less state.
illustrates this result for the peak corresponding to the 1225 wavelength
of the PU sample loaded with 10% mass of Flector. It can be detected
that the amplitude of this peak decreases with time. A comparison
between the spectra of three differently loaded samples is also pro-
posed. Fig. 13 compares the amplitudes of the peak corresponding to
the wavelength 1225 of PU samples loaded with 10%, 20% and 30%
mass of Flector at the flow-less state for different time steps of the test.
Notable differences are observed at various times in vitro. The peak
amplitude of the samples with higher percentage of drug decreases
more rapidly with time. In conclusion, it is patent the IR analysis could
represent a relevant tool to study the drug release.
4.2. Effect of drug content on drug release and water absorption
This study was regarded around the release kinetics and possible
mechanisms with considering the effects of various percentages of drug
(10, 20, 30% of Flector) at the temperature of 37 °C in flow-less and
continuous state with different flow rates from the blood flow at the rest
time 6.5–7.5 ml/s up to the exercising time 23.5 ml/s.
4.2.1. Flow-less tests
Fig. 14(a) shows the wet mass of the samples, which is the mass
variation, related to the competition between increase of the mass be-
cause of the water absorption and decrease of the mass because of the
dug loss. Fig. 14(b) shows the water absorption rates for four various
cases, pure-PU and PU with drug loading 10, 20 and 30% mass of
Flector. It is mentioned that the water penetrates even in the pure-
polymer, but with a modest value, close 5%. In contrast, for the loaded
PUs this rate increases with the initial drug rate. It reaches 70% rate of
the water absorption for the most loaded case. The presence of the drug,
therefore, plays a leading role in the absorption of water. This is true
that the hydrophilic property of the chosen drug is high. It is notable
that the values in the percentage of water absorption is affected also by
the difference of the density of water and diclofenac which are re-
spectively 997 and 450.7 mg/l where they are occupying the same
space but with a heavier weight for the water. Fig. 14(c) shows the drug
release ratios for the three loaded PU cases. Comparing the three curves
of the PU with 10, 20, and 30% of drug, it is apparent that along with
increasing the drug content there is a decrease in the maximum time of
the release. For the samples, which receive the significant increase of
the peak during the premier days of experiment further, they have high
decrease in the mass. Which means that samples with significant per-
centage of drug absorb more percentage of the water (initial period of
the curve) and then substance which has absorbed water has left the
polymer matrix with the water so the sample is influenced by the mass
decrease relating to the drug release (secondary period of the curve). To
highlight the water absorption phenomenon and drug release behavior
of PU with various percentages of drug, different analysis has been
performed. Error bars have not been shown as they are hidden behind
the symbols. Note that the maximum standard deviation is about 3.1%
Fig. 15. a) Wet mass b) Water absorption and c) Drug release for different percentage of drug at steady flow with flow rate of Q = 7.5 ml/s.
and minimum is about 0.08% wherein the average is about 1.8%.
4.2.2. Steady flow tests
The results of wet mass, water absorption and drug release for
continuous condition, Q = 7.5 ml/s are presented in Fig. 15. In this
figure, one can note the effect of the drug charge on the results. Com-
paring the results of the water absorption for the tests with the flow rate
of 7.5 ml/s and with different percentage of drug, it indicates water can
penetrate into the polymer about 32% in the case of PU with 10% drug,
and it is slowly increasing by the drug percentage to 56% PU with 30%
drug. From the slope of second part of the curve, one can note the same
mechanism of drug release in this condition at different drug percen-
tage Fig. 15(c). Globally, the same behavior of water absorption and
drug release can be seen in continuous case and flow-less state one.
Evidently, in the case of continuous tests, the time is the scale of hours.
Fig. 16 is representing the effect of flow rate on the wet mass, water
absorption and the drug release of the samples with 10% of the drug.
Fig. 16(a) illustrates there is not high differences in wet mass of the
numerous samples at various flow rates for PU with 10% drug.
Fig. 16(b) illustrates there is not high differences in water absorption of
the numerous samples at various flow rates for PU with 10% drug.
Fig. 16(c) indicates the effect of the flow rate on the drug release. One
can note that by increasing the flow rate the rate of the drug released in
accordance to the time is increasing. It is notable to indicate that the
applied parameters (drug percentage and flow rate) have changed the
release behavior but to note about the effect of these parameters on the
whole objective which is the therapy of the diseased area, it is better to
further study it in the tissue area for seeing the biological effect of these
parameters. In a study by McKittrick et al. [48] they have resulted that
although the medicament in high dose stents don't stay a long time in
the stent comparing to the low dose, but it stays longer time binded to
the receptors in the tissue, which are evidently depending to the bio-
logical characters of the drug and the tissue.
5. Conclusions
Polyurethane-based films loaded with different doses of Flector are
used to study the drug release as well as the water absorption under
various flow conditions. SEM analysis of Flector granules showed that
the average particle size of this drug was about 40 μm. Two families of
tests were considered: case with steady flow and flow-less. The results
show that water absorption by pure polyurethane is also present in this
case, but with a low rate, about 5%. This rate increases with drug
loading which can reach up to about 65% of the sample mass.
Additionally, the rate of the released drug increases with the drug
loading, and it is increasing with the flow rate. Several mechanisms can
account for the increment in relative release rates at increasing drug
loading, such as faster water influx and hence faster dissolution at
higher drug loading (because of osmotic effects) or connectivity of drug
loaded particles.
Fig. 16. a) Wet mass b) Water absorption and c) Drug release for PU with 10% of Flector at different flow rates.
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